| Detailed information |
|---|
| CancerLivER ID | 2138 |
| Biomarker | ANGPTL4 |
| Biomarker Name/Symbol (given in Publication) | ANGPTL4 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | useful markers to evaluate the size and prognosis of liver cancer; but not validated on independent dataset |
| Experimental Condition | Normal vs HCC; predict survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in paracancerous than in cancerous liver tissue |
| Level of significance | p < 0.0001 |
| Source | Tissue |
| PMID | 23251252 |
| Type of Biomarker | Prognostic |
| Pathway | TGFβ signaling pathway |
| Cohort | 280 patients with HCC who underwent surgery to remove liver cancer between 2005 and 2011 in our hospital (Fudan University, Shanghai, China). |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2013 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |